Phosphate binder usage in kidney failure patients

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 6, 2003, Pages 941-947

  Bleyer, Anthony J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Aluminum; Binders; Calcium acetate; Calcium carbonate; Calcium phosphate; Haemodialysis; Iron complex; Osteodystrophy; Peritoneal dialysis; Sevelamer

Indexed keywords

2 OXOGLUTARIC ACID; ALUMINUM HYDROXIDE; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM CHANNEL STIMULATING AGENT; CARBONIC ACID DERIVATIVE; DIGOXIN; FERRIC HYDROXIDE; IRON COMPLEX; LANTHANUM; PHOSPHATE BINDING AGENT; PHOSPHORUS; SEVELAMER; VITAMIN D DERIVATIVE; WARFARIN;

ALUMINUM OVERLOAD; BLOOD VESSEL CALCIFICATION; BRAIN DISEASE; CLINICAL TRIAL; CONSTIPATION; COST BENEFIT ANALYSIS; DIARRHEA; DIET RESTRICTION; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DRUG BINDING; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG STRUCTURE; DYSPEPSIA; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; PHOSPHATE METABOLISM; REVIEW; STRUCTURE ACTIVITY RELATION; URINARY EXCRETION;

ACETATES; ALUMINUM COMPOUNDS; CALCIUM CARBONATE; CLINICAL TRIALS; EPOXY COMPOUNDS; HUMANS; IRON COMPOUNDS; KETOGLUTARIC ACIDS; KIDNEY FAILURE, CHRONIC; LANTHANUM; PHOSPHATES; POLYAMINES; POLYETHYLENES; RENAL DIALYSIS;

EID: 0038009087     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.6.941     Document Type: Review

References (43)

1. SUKI W, ROUSE D: Renal transport of calcium, magnesium, and phosphate. In: The Kidney, 5th edn. Brenner BM (Ed.), WB Saunders Company, Philadelphia, USA (1996):495-496.
2. SLATOPLSKY E, CAGLAR S, PENNELL JP et al.: On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J. Clin. Invest. (1971) 50:492-499.
3. MASSRY SG, KOPPLE JD: Requirements for calcium, phosphorus, and vitamin D. In: Handbook of Nutrition and the Kidney. Mitch WE, Klahr S (Eds), Lippincott Williams & Wilkins, Boston, USA (1993):96-113.
4. POHLMEIER R, VIENKEN J: Phosphate removal and hemodialysis conditions. Kidney Int. (2001) 59(Suppl. 78):S190-S194.
5. HOU S, ZHAO J, ELLMAN CF, HU J, GRIFFIN Z, SPIEGEL DM et al.: Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am. J. Kidney Dis. (1991) 18:217-224.
6. CHAUVEAU P, POIGNET JL, KUNO T et al.: Phosphate removal rate: a comparative study of five high-flux dialysers. Nephrol. Dial. Transplant. (1991) 6(Suppl. 2):114-115.
7. HOU S, ZHAO J, ELLMAN CF et al.: Calcium and phosphorus fluxes during hemodialysis with low calcium dialysate. Am. J. Kidney Dis. (1991) 18:217-224.
8. TRAEGER J, GALLAND R, FERRIER ML, DELAWARI E: Optimal control of phosphatemia by short daily hemodialysis. J. Am. Soc. Nephrol. (2002) 13:410A-411A.
9. SEDLACEK M, DIMAANO F, URIBARRI J: Relationship between phosphorus and creatinine clearance in peritoneal dialysis: clinical implications. Am. J. Kidney Dis. (2000) 36:1020-1024.
10. SCHILLER L, SANTA ANA CA, SHEIKH M et al.: Effect of the time of administration of calcium acetate on phosphorus binding. N. Engl. J. Med. (1989) 320:1110-1113.
11. SHEIKH M, MAGUIRE JA, EMMETT M et al.: Reduction of dietary phosphorus absorption of phosphorus binders: a theoretical, in vitro, and in vivo study. J. Clin. Invest. (1987) 83:68-73.
12. ANDRESS DL, KOPP JB, MALONEY NA, COBURN JW, SHERRARD DJ: Early deposition of aluminum in bone in diabetic patients on hemodialysis. N. Engl. J. Med. (1987) 316:292-296.
13. ALFREY AC, LEGENDRE GR, KAEHNY WD: The dialysis encephalopathy syndrome: possible aluminum intoxication. N. Engl. J. Med. (1976) 294:184-188.
14. LAU AH, KUK JM, FRANSON KL: Phosphate-binding capacities of calcium and aluminum formulations. Int. J. Art. Organs (1998) 21:19-21.
15. ROSS EA, SZABO M, TEBBETT IR: Lead content of calcium supplements. JAMA (2000) 284:1425-1429.
16. 2-receptor antagonist on the phosphorus-binding abilities of calcium carbonate and calcium lactate in hemodialysis patients. J. Am. Soc. Nephrol. (1999) 10:1090-1094.
17. STAMATAKIS MY, ALDERMAN JM, MEYER-STOUT PJ: Influence of pH on in vitro disintigration of phosphate binders. Am. J. Kidney Dis. (1998) 32:808-812.
18. KOBRIN SM, GOLDSTEIN SJ, SHANGRAW RF, RAJA RM: Variable efficacy of calcium carbonate tablets. Am. J. Kidney Dis. (1989) 14:461-465.
19. MAI ML, EMMETT M, SHEIKH MS, SANTA ANA CA, SCHILLER L, FORDTRAN JS: Calcium acetate, an effective phosphorus binder in patients with renal failure. Kidney Int. (1989) 36:690-695.
20. EMMETT M, SIRMON MD, KIRKPATRICK WG, NOLAN CR et al.: Calcium acetate control of serum phosphorus in hemodialysis patients. Am. J. Kidney Dis. (1991) 17:544-550.
21. DELMEZ JA, TINDIRA CA, WINDUS DW, NORWOOD KV et al.: Calcium acetate as a phosphorus binder in hemodialysis patients. J. Am. Soc. Nephrol. (1992) 3:96-102.
22. RIEDEL E, HAMPL H, STEUDLE V, NUNDEL M: Calcium alpha-ketoglutarate administration to malnourished hemodialysis patients improves plasma arginine concentrations. Miner. Electrolyte Metab. (1996) 22:119-122.
23. BIRCK R, ZIMMERMANN E, WASSMER S, NOWACK R, VAN DER WOUDE FJ: Calcium ketoglutarate versus calcium acetate for treatment of hyperphosphatemia in patients on maintenance hemodialysis: a cross-over study. Nephrol. Dial. Transplant. (1999) 14:1475-1479.
24. BRO S, RASMUSSEN RA, HANDBERG J, OLGAARD K, FELDT-RASMUSSEN B: Randomized crossover study comparing the phosphate-binding efficacy of calcium ketoglutarate versus calcium carbonate in patients on chronic hemodialysis. Am. J. Kidney Dis. (1998) 2:257-262.
25. HSU CH: Are we mismanaging calcium and phosphate metabolism in renal failure. Am. J. Kidney Dis. (1997) 29:641-649.
26. KURZ P, MONIER-FAUGERE MC, BOGNAR B et al.: Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. (1994) 46:855-861.
27. KUZELA DC, HUFFER WE, CONGER JD, WINTER SD, HAMMOND WS: Soft tissue calcification in chronic dialysis patients. Am. J. Pathol. (1977) 86:403-424.
28. BLEYER AJ, CHOI M, IGWEMEZIE B, DE LA TORRE E, WHITE WL: A case control study of proximal calciphylaxis. Am. J. Kidney Dis. (1998) 32: 376-383.
29. GOODMAN WG, GOLDIN J, KUIZON BD et al.: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. (2000) 342:1478-1483.
30. SPERSCHNEIDER H, GUNTHER K, MARZOLL I, KIRCHNER E, STEIN G: Calcium carbonate: an efficient and safe phosphate binder in haemodialysis patients? A 3-year study Nephrol. Dial. Transplant. (1993) 8:530-534.
31. RAGGI P: Coronary calcium on electron beam tomographic imaging as a surrogate marker of coronary artery disease. Am. J. Cardiol. (2001) 87:(4A): 27A-34A.
32. BLEYER AJ, BURKE SK, DILLON M et al.: A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am. J. Kidney Dis. (1999) 33:694-701.
33. CHERTOW GM, BURKER SK, RAGGI P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. (2002) 62:245-252, 2002
34. RAGGI P, BOULAY A, CHASAN-TABER S et al.: Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J. Am. Coll. Cardiol. (2002) 39:695-701.
35. WALTERS BA, DELAHUNTY MI, NABUT JL, PENNELL P, BOSCH JP: Reduction in cardiac mortality in hemodialysis patients on sevelamer hydrochloride compared with phosphate binders containing calcium. J. Am. Soc. Nephrol. (2002) 13:596A
36. MCINTYRE CW, PATEL V, TAYLOR GS, FLUCK RJ: A prospective study of combination therapy for hyperphosphatemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients. Nephrol. Dial. Transpl. (2002) 17:1643-1648.
37. BURKE S, AMIN N, INCERTI C, PLONE M, WATSON N: Sevelamer hydrochloride (Renagel), a nonabsorbed phosphate-binding polymer, does not interfere with digoxin or warfarin pharmacokinetics. J. Clin. Pharmacol. (2001) 41:193-198.
38. GALLIENI M, COZZOLINO M, BRANCACCIO D: Transient decrease of serum bicarbonate levels with sevelamer hydrochloride as the phosphate binder. Kidney Int. (2000) 57:1776-1777.
39. HUTCHISON AJ: Calcitriol, lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy. Perit. Dial. Int. (1999) 19(Suppl. 2):S408-S412.
40. JOY MS, FINN WF: Fosrenol, a novel non-calcium, non-aluminium phosphate binder, has a good safety and efficacy profile in the long-term treatment of hyperphosphatemia. J. Am. Soc. Nephrol. (2002) 13:386A.
41. HERGESELL O, RITZ E: Phosphate binders in uraemia: pharmacodynamics, pharmacoeconomics, pharmacoethics. Nephrol. Dial. Transplant. (2002) 17:14-17.
42. 3. Kidney Int. (1999) 56(Suppl. 73): S46-S52.
43. GOODMAN WG, HLADIK GA, TURNER SA: The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J. Am. Soc. Nephrol. (2002) 13:1017-1024.